Last week, @PharmToTablePod dropped the 1st in a series of episodes dealing with nucleoside chemistry. In this three part series we will walk you thru different types of challenges with these molecules at different stages of drug discovery. #MerckChemistrypodcasts.apple.com/us/podcast/pha…
Given that we are dedicating 3 episodes on this topic, I thought it would be good to offer some baseline nucleoside basics for you in case you aren’t familiar with this topic, in this 🧵 I’ll call #Nuceloside101
The relevance of these building blocks in pharma is largely driven by their importance in the biology, particularly RNA and DNA. These nucs vary by the hydroxylation pattern. #Nucleoside101
Generally speaking nucleosides are composed of 2 major parts: the base and the sugar. Here is an example with uridine. #Nucleoside101
There are common bases for nucleosides. Here are the most common. #Nucleoside101
You may have heard of nucleoTIDES too! There is a difference. It’s the phosphorylation! #Nucleoside101
In the episode we talk about specific chemistry as specific carbons on the ribose scaffold. These are the positions where unnatural therapeutic nucleosides are often modified for SAR studies. #Nucleoside101
Finally, in the episode we also talk about “exotic” analogues. Some of the ones we discuss look like this. #Nucleoside101
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Authored this thread in support of #YoungScientistNetworking, to let you know a little more about my training and career path. I’m writing in free form, stream of consciousness, so feel free to reach out with specific questions or missing links in the 🧵1/..
I grew up in a small border town in Ontario, Canada on the St-Lawrence river. I am the youngest of 5 kids. My 1st language is French. Didn’t speak English until around grade 2. As a child I was interested in how stuff worked and asked a lot of questions. 2/..
In high school I became inspired to pursue STEM subjects via great teachers I had. I was the 1st in my family to have any interest in science and I ultimately decided to pursue a B.Sc. In biopharmaceutical sciences in FTE school at @uOttawa. 3/..
I am very disturbed and disappointed by Prof. Hudlickly's comments in this article in @angew_chem where he makes the case that “diversity of the workforce” has a ”negative impact” on the field of organic synthesis (see the ridiculous figure!) onlinelibrary.wiley.com/doi/epdf/10.10…
The insinuation he makes is that providing support of under-represented individuals and inclusion practices “results in discrimination against the most meritorious” individuals is ridiculous. This is completely preposterous! 2/x
As an experienced recruiter and a leader of a chemistry group in the pharmaceutical sector, I can tell you that these views are not only factually wrong, they represent the exact types of biases that the field has been trying to overcome. I encourage other leaders to denounce it!